Spencer Feldman

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates dropping to about 4% after seven years.

Adrenal cancer is rare, but surgery, medicines, chemotherapy and clinical trials can help patients based on stage, spread and overall health.

Inluriyo, an oral therapy for ER+, HER2– metastatic breast cancer with ESR1 mutations, offers a new treatment option after prior endocrine therapy.

A study found that iberdomide with Darzalex and dexamethasone helped more patients with multiple myeloma reach no signs of cancer after treatment.

The FDA grants fast track status to alnodesertib plus low-dose irinotecan for third-line metastatic colorectal cancer with ATM deficiency.

Dr. Christina Cho explains that a strong transplant program provides advanced treatments along with a supportive team for patients with blood cancers.

Tecvayli and Darzalex demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

Molecular testing helps distinguish kidney cancer subtypes, ensuring patients get accurate diagnoses and treatment plans, avoiding unnecessary surgery.

Giredestrant plus Afinitor improved survival without progression in ER-positive advanced breast cancer.

Learn how myelodysplastic syndrome treatment has advanced with targeted therapies and anemia management while balancing quality of life for patients.

A guide for patients to understand HER2-positive breast cancer, treatment options by stage and how to talk with your oncologist.

The FDA granted orphan drug designation to ligufalimab for AML, reflecting its potential as an immune-based therapy that may offer new options for patients.

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.

The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.

Chemotherapy can trigger early menopause, while strategies and new data on pausing therapy may help women protect fertility and plan pregnancy.

Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma.

Colorectal cancer is a complex disease. Understanding its fundamental aspects can empower you to have more informed and productive conversations with your oncologist.

Rising colorectal cancer rates in younger adults are prompting earlier screenings, with colonoscopy offering both detection and prevention.

PredicineCARE, a urine-based test, is under FDA review as a companion diagnostic for bladder cancer, building on previous data and biomarker insights.

The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent stage 2 colorectal cancer.

The FDA approved Bildyos and Bilprevda as biosimilars to Prolia and Xgeva, expanding bone care options for osteoporosis, cancer and more.

Lung cancer affects up to 25% of non-smokers, so persistent symptoms and genetic testing are key for early detection and treatment.

The FDA approved Monjuvi with Revlimid and Rituxan for follicular lymphoma, the same combination that brought survivor Troy Anderson a lasting response.

Hideko Warner shared how she faced three cancers at once and became the first in Orange County to receive biology-guided radiation therapy with no side effects.

Non-drug therapies, counseling and telehealth improved pain, mood and communication in cancer care, though older adults and minorities remain underrepresented.

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment.

A survivor shares how family, care teams and mentoring others helped her face stage 3C ovarian cancer and reclaim independence with hope.

Dena Champion, dietician, explains how taste/smell changes from cancer treatment can make eating difficult and affect recovery.